Halozyme Therapeutics Announces Hiring of New Leadership for Business Development
SAN DIEGO, Oct. 28 /PRNewswire-FirstCall/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced that William F. Daly has joined the company as vice president of business development. Mr. Daly has held a number of business development positions where he screened, evaluated, conducted the due diligence, and consummated corporate transactions at such companies as Cougar Biotechnology, Allergan, Chiron and Novartis. He has also fulfilled a similar role with several start-up biotechnology companies, and has expertise in the negotiation of deal structures and in the integration and management of partnerships and alliances.
"I am pleased to welcome Bill Daly to Halozyme's senior management team," stated Jonathan Lim, M.D., president and CEO. "We will leverage Bill's broad experience and successful record of achievement to fulfill this vital role and to help shape the future direction of Halozyme's business development effort."
Mr. Daly joins Halozyme from Cougar Biotechnology, where he served as senior vice president of business development. Following the acquisition of Cougar by Johnson & Johnson, Mr. Daly co-led the integration of Cougar and J&J and was also site head of the Los Angeles facility. Prior to Cougar, Mr. Daly served as vice president, corporate development at Allergan where he was head of neurosciences business development and head of European business development.
Before moving into the biopharma industry, Mr. Daly was an investment banker and practiced corporate and securities law. He graduated from the University of California, Berkeley with an A.B. in biochemistry and earned his law degree and an MBA from the University of California, Los Angeles.
Halozyme Therapeutics is a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the endocrinology, oncology, dermatology and drug delivery markets. The company's product portfolio is based primarily on intellectual property covering the family of human enzymes known as hyaluronidases and additional enzymes that affect the extracellular matrix. Halozyme's EnhanzeTM technology is a novel drug delivery platform designed to increase the absorption and dispersion of biologics. The company has key partnerships with Roche to apply Enhanze technology to Roche's biological therapeutics, including Herceptin® and MabThera®, for up to 13 targets, and with Baxter BioScience to apply Enhanze technology to immunoglobulin. Halozyme's Ultrafast Insulin program combines its rHuPH20 enzyme with mealtime insulins, which may produce more rapid absorption, faster action, and improved glycemic control. The product candidates in Halozyme's pipeline target multiple areas of significant unmet medical need. For more information visit www.halozyme.com.
Safe Harbor Statement
In addition to historical information, the statements set forth above include forward-looking statements (including, without limitation, statements concerning the expected roles and responsibilities of management) that involve risk and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. The forward-looking statements are also identified through use of the words "believe," "enable," "may," "will," "could," "intends," "estimate," "anticipate," "plan," "predict," "probable," "potential," "possible," "should," "continue," and other words of similar meaning. Actual results could differ materially from the expectations contained in forward-looking statements as a result of several factors, including regulatory approval requirements and competitive conditions. These and other factors that may result in differences are discussed in greater detail in the company's reports on Forms 10-K, 10-Q, and other filings with the Securities and Exchange Commission.